The first part of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.
News|Articles|November 1, 2004
Nebivolol: A beta antagonist with novel pharmacologic properties
Nebivolol is a beta-blocker under FDA review for the treatment of hypertension. Nebivolol has unique pharmacologic properties, including high specificity for the beta-1 receptor and a nitric oxide-mediated vasodilatory effect. The agent provides significant blood pressure reduction from baseline values and as compared to placebo. Clinical trials have demonstrated that nebivolol reduces blood pressure similarly to atenolol, bisoprolol, amlodipine, nifedipine, lisinopril, and hydrochlorothiazide. The tolerability of nebivolol is similar to or better than that of these agents. If approved, nebivolol would likely be a viable alternative therapy for hypertension; however, additional studies are needed in patients with heart failure and coronary artery disease.
Advertisement
Advertisement
Related to this article
Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.
Christopher Stanley, M.D., MBA, says Henry Ford Health's growth has led Populance to put its push for outside customers on hold and focus on its own system.
Geisinger Health Plan President Jeremy Gaskill says being owned by a health system aligns incentives, cuts payer-provider busywork and speeds care to patients.
Geisinger Health Plan expects Medicaid enrollment to fall roughly 10% as H.R. 1 takes effect, President Jeremy Gaskill says, though the timing is still unclear.
As other insurers pull back, Geisinger Health Plan isn’t exiting any Medicare Advantage plans for 2027 and expects to grow, President Jeremy Gaskill says.
The second part of our interview with Jeremy Gaskill, the president of the Geisinger Health Plan. Gaskill discusses trends in the various segments of the health insurance market—Medicaid, Medicare Advantage, the employer-based commercial market and the ACA marketplace.
Democrats won Congress, but with Trump’s veto, their best healthcare tools are funding bills, hearings and bipartisan deals.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
On Medicaid cuts, the Medicare Advantage market, commercial insurance and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
2
The CVS Health split. How separate will the two companies really be?
3
CVS Health is splitting in two, according to news reports
4
On the advantages of health system-owned health plan, what Medicaid cuts might mean and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
5